$500m And Counting: Vir Puts Big Money To Work In Infectious Diseases
Vir Biotechnology launched in January with $150m and a focus on infectious diseases. Now, the George Scangos-led venture has raised more than $500m and signed multiple collaboration agreements, including deals with Alnylam and Visterra worth as much as $1bn each.
You may also be interested in...
BioNTech's $150m offering, after a prior large venture capital financing, gives it the third-largest market cap for a newly public drug developer in the US. Also, Innovent raises $300m in Hong Kong offering, Heron leads US follow-ons and Five Prime restructures to save $20m annually.
Public Company Edition: Bellus launched the first biopharma IPO in the US since mid-July and Vir Biotechnology, run by former Biogen CEO George Scangos, wants to raise $100m. Also, Turning Point's $202.5m offering and Zafgen's strategic review.
As it narrows focus to core therapeutic areas ahead of acquiring Shire, Takeda sends uterine fibroid and endometriosis rights to compatriot firm ASKA. Zai Lab and Crescendo team up on antibody candidate for inflammatory indications.